Recognised for its research excellence in 2025, the Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) secured the Research & Development Achievement Award at the Pharma Industry Awards 2025, celebrated for its groundbreaking work in ocular drug delivery, sustainability-focused laboratory operations, and support for dynamic spinouts.

The centre’s initiatives demonstrated a commitment to translating scientific discovery into practical healthcare solutions, integrating environmental sustainability and real-world applicability into every project. PMBRC’s research has delivered major advancements in ophthalmic therapeutics, contributed to European funding success, and fostered a culture of innovation that supports both economic growth and societal impact.

Judges commended the centre’s depth of expertise and forward-thinking approach: “PMBRC stood out for its pioneering research in ocular drug delivery, sustainability-led lab practices, and exceptional support for spinouts,” the judging panel said. “The centre demonstrates a culture of progress, combining scientific rigor with real-world relevance and measurable impact on healthcare and the life sciences sector.”

The recognition reflects the evolving standards of the Pharma Industry Awards, where winners are celebrated for combining technical innovation, operational excellence, and societal impact. PMBRC’s achievement illustrates how cutting-edge research, sustainability, and community engagement can set benchmarks for the pharmaceutical R&D sector.

With exceptional leadership from the 2025 winners, attention now turns to the next awards cycle. Who will define the next era of innovation, scientific excellence, and patient-focused biotech leadership in 2026?

For years, the Pharma Industry Awards have highlighted organisations and centres driving scientific advancement, innovation, and measurable impact in pharmaceutical research and development.

Visit the official awards website to explore past winners, read more about their achievements, and subscribe to the newsletter for updates and insights.